The company's solutions:
The only blood test-of-its-kind (Epi+Gen CHD) in the world to offer personalized (epigenetics-based) insights into coronary heart disease drivers and assess the risk of a heart attack in the next three years. This risk assessment test evaluates five single nucleotide polymorphisms (SNPs) and three DNA methylation markers in genomic DNA isolated from human peripheral whole blood specimens.
The only blood test-of-its-kind in the world (PrecisionCHD) to detect the presence of coronary heart disease (epigenetics-based). ...
Profile
Support
Implementation
Product
Potential
People
Communications
Technology
Vision
Data
Flexibility
Create a free account to instantly unlock full reviews breakdown and to read reviews.
Employer Implementation (1).pdf
Precision Cardiovascular Risk Solutions for Broker & Benefits Orgs..pdf
Employee Journey Infographic (1).pdf
You must be a registered user of Shortlister to access this information.
To access these
documents, claim a free account.